An observational study in Heart Failure, Valvular Heart Disease and Aortic Stenosis, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-12.
Sponsored by Erasmus Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.
Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 45th largest by planned enrollment of the 76 observational ones that give a count, is one of 17 that started in 2022, is one of 76 observational ones, reaches primary completion later than 6 of the 79 other live ones, and was the 251st registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Netherlands, United States, Argentina and 29 more countries
Ages 18+
Eli Lilly and Company · Sites in Netherlands, United States, Japan and 2 more countries
Ages 18–65
Jasper Brugts MD PhD · Sites in Netherlands
Ages 18+
BrioHealth BV · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
313 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 55 · Phase 3 68 · Phase 4 12
First in 1983; this study’s year is marked. 17 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 157 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 284 across the 234 interventional studies, 236 across the 76 observational. Of the 200 that completed or were terminated, 84 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
179 of 313 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 9 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
15 of the studies in Heart Failure with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06137261Franciscus GasthuisScreening Adults With Obesity to Reduce Heart Failure Events | 2026-12-08 |
| NCT06735404Radboud University Medical CenterRAPIDE: The Feasibility of a Hybrid Care Model | 2027-03 |
| NCT06641362VDI TechnologiesUltra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED) | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 313 studies in Heart Failure with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of PLUTO-II is to use biventricular pressure-volume (PV) loop measurements to improve the understanding of direct changes in cardiac and hemodynamic physiology induced by transcatheter aortic valve implantation (TAVI) or tricuspid edge-to-edge repair (TEER). These procedures evoke immediate changes in cardiac mechanoenergetics, ventricular-vascular interaction as well as ventricular (in)dependency. Within the context of PLUTO-II, patients will undergo biventricular PV-loop measurements before and after TAVI or TEER. In future, the application of perprocedural PV loop monitoring may tailor the daily individual decision making process during structural interventions in the catheterization laboratory.
Pressure-Volume (PV) loop monitoring is a tool allowing direct visualization of individual cardiac and hemodynamic physiology, including parameters reflecting cardiac mechanoenergetics (a derivative of the myocardial metabolic demand) as well as the ventricular-arterial coupling. The concepts of changing biventricular cardiac and hemodynamic physiology induced by structural heart interventions, including Transcatheter Aortic Valve Implantation (TAVI), Transcatheter Edge-to-Edge Mitral Repair (mitral TEER) and Transcatheter Edge-to-Edge Tricuspid Repair (tricuspid TEER) are largely based on hypotheses, computer simulations and non-invasive (echocardiographic) estimations. PVL monitoring has the potential to identify unique characteristics of TAVI, mitral TEER and tricuspid TEER from the perspective of changing baseline cardiovascular physiology, including (a change in) interference between both ventricles (i.e. the ventricular crosstalk). Perprocedural (biventricular) PV loop monitoring can be of direct clinical relevance by appreciating the ventricular tolerance of increased cardiac afterload induced by the particular intervention in individual patients. In future, real-time PV loop analysis can be adjunctive to the individual decision-making process during routine structural interventions.
Adult patients undergoing elective TAVI or mitral TEER.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elective TAVI with biventricular PV loop monitoring (throughout the procedure)
Other: Pressure volume (PV) loop measurement
Elective mitral TEER with biventricular PV loop monitoring (throughout the procedure)
Other: Pressure volume (PV) loop measurement
Elective tricuspid TEER with biventricular PV loop monitoring (throughout the procedure)
Other: Pressure volume (PV) loop measurement
Pressure volume (PV) loop measurement using a conductance catheter
Cardiac mechanoenergetics
The change in cardiac mechanoenergetics (stroke work, potential energy and pressure-volume area in mmHg/mL) induced by the particular procedure
Time frame: Periprocedural time window
Stroke volume (mL)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
Preload recruitable stroke work (mmHg/mL)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
Tau (ms)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
Intraventricular dyssynchrony (%)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
dP/dt min and dP/dt max (mmHg/sec)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
End-systolic elastance (Ees) and arterial elastance (Ea) (mmHg/mL)
With Ees/Ea ratio reflecting ventricular-vascular coupling
Time frame: Periprocedural change (directly before vs. after the procedure)
End-systolic and end-diastolic volume (mL)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
End-systolic and end-diastolic pressure (mmHg)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
Starling Contractile Index (mmHg/mL)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
V0, V15, V30 and V100 mmHg (mL)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
SW/PVA ratio (based on the primary outcome)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
Beta (ventricular stiffness constant, unitless)
Based on perprocedural conductance catheter measurements
Time frame: Periprocedural change (directly before vs. after the procedure)
Mortality
All-cause
Time frame: 30-day follow-up
Hospital stay
in days
Time frame: 30-day follow-up
Postprocedural morbidity (%)
including acute kidney failure, cardiac decompensation and unexpected need for vasopressor or inotropic support (all yes/no)
Time frame: 30-day follow-up
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for May 2024, 18 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 18 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.